Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of Tirzepatide as a treatment for type two diabetes.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources. NICE is currently appraising Tirzepatide for the treatment of type 2 diabetes through its technology appraisal programme and expects to publish final guidance in April 2023.